AUTHOR=Khan Maliha , Carmona Selena , Sukhumalchandra Pariya , Roszik Jason , Philips Anne , Perakis Alexander A. , Kerros Celine , Zhang Mao , Qiao Na , John Lisa S. St. , Zope Madhushree , Goldberg Jonathan , Qazilbash Mariam , Jakher Haroon , Clise-Dwyer Karen , Qiu Yihua , Mittendorf Elizabeth A. , Molldrem Jeffrey J. , Kornblau Steven M. , Alatrash Gheath TITLE=Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target JOURNAL=Frontiers in Immunology VOLUME=8 YEAR=2018 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01975 DOI=10.3389/fimmu.2017.01975 ISSN=1664-3224 ABSTRACT=
Cathepsin G (CG) is a myeloid azurophil granule protease that is highly expressed by acute myeloid leukemia (AML) blasts and leukemia stem cells. We previously identified CG1 (FLLPTGAEA), a human leukocyte antigen-A2-restricted nonameric peptide derived from CG, as an immunogenic target in AML. In this report, we aimed to assess the level of CG expression in acute lymphoid leukemia (ALL) and its potential as an immunotherapeutic target in ALL. Using RT-PCR and western blots, we identified CG mRNA and protein, respectively, in B-ALL patient samples and cell lines. We also examined CG expression in a large cohort of 130 patients with ALL